Lorcaserin treatment decreases body weight and reduces cardiometabolic risk factors in obese adults: A six‐month, randomized, placebo‐controlled, double‐blind clinical trial

Lorcaserin is a serotonin 2c receptor agonist that promotes weight loss while contributing to the prevention and improvement of type 2 diabetes and improvement of atherogenic lipid profiles, without higher rates of major cardiovascular events. The full spectrum of possible lorcaserin‐induced improve...

Full description

Saved in:
Bibliographic Details
Published in:Diabetes, obesity & metabolism obesity & metabolism, 2019-06, Vol.21 (6), p.1487-1492
Main Authors: Tuccinardi, Dario, Farr, Olivia M., Upadhyay, Jagriti, Oussaada, Sabrina M., Mathew, Hannah, Paschou, Stavroula A., Perakakis, Nikolaos, Koniaris, Anastasia, Kelesidis, Theodoros, Mantzoros, Christos S.
Format: Article
Language:English
Subjects:
Anti-Obesity Agents - adverse effects
Anti-Obesity Agents - pharmacology
Anti-Obesity Agents - therapeutic use
Appetite
Benzazepines - adverse effects
Benzazepines - pharmacology
Benzazepines - therapeutic use
Body fat
Body weight
Body Weight - drug effects
Body weight loss
cardiovascular disease risk
Cardiovascular diseases
Clinical trials
Diabetes mellitus
Diabetes mellitus (non-insulin dependent)
Double-Blind Method
Double-blind studies
Energy expenditure
Energy intake
Energy Intake - drug effects
Energy Metabolism - drug effects
Evidence-based medicine
Fatty liver
Female
Gene expression
Health risk assessment
Heart rate
High density lipoprotein
Humans
Lipid peroxidation
Lipids
Lipoproteins - blood
lorcaserin
Low density lipoprotein
Male
Middle Aged
Obesity
Obesity - drug therapy
Risk factors
Weight control
weight loss
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Lorcaserin is a serotonin 2c receptor agonist that promotes weight loss while contributing to the prevention and improvement of type 2 diabetes and improvement of atherogenic lipid profiles, without higher rates of major cardiovascular events. The full spectrum of possible lorcaserin‐induced improvements in cardiometabolic health remains to be clarified. Thus, we investigated the way in which lorcaserin treatment may alter cardiovascular disease risk, either independently or through changes in body weight. We measured, for the first time, lipid particle quantification, lipid peroxidation, appetite‐regulating hormones and mRNA expression of the 5‐hydroxytryptamine 2c receptor (5‐HT2c receptor). A total of 48 obese participants were enrolled in this six‐month, randomized (1:1), placebo‐controlled, double‐blinded clinical trial. Lorcaserin treatment reduced fat mass (P 
ISSN:1462-8902
1463-1326
DOI:10.1111/dom.13655